bluuebunny/crossref_metadata_2025_split huggingface dataset:
1345-P: Burden of Injury among People with Type 1 and Type 2 Diabetes
Authors: FELEKE BERHANU E. , AND INJURY DIABETES 
Published: June 2024

Introduction & objective: The risk of injury in people with diabetes is not well described. This study was conducted to estimate the risk and excess hospitalisation rate for injury in people with diabetes compared to the general population.
Methods: Data were obtained from the Australian National Diabetes services scheme, Hospitalisation Datasets, the Pharmaceutical Benefits Scheme, the National Death Index, and the national census from 2011-2017. Hospitalisations for injury were coded into the following categories: head, lower extremity, upper extremity, abdominal, vertebral, burns, and other injury. Poisson regression was used to estimate the relative risk (RR) and excess hospitalisation of injury in those with diabetes compared to the general population.
Results: In this study, there were 97,917 admissions among people with diabetes and 3,463,173 among the general population. Compared to the general population, the age, sex, and calendar year adjusted risk of admission for any injury (RR 1.01 [95% CI: 1.01, 1.02]), head injury (1.14 [1.12, 1.15]), burn (1.30, [1.23, 1.39]), and other injury (1.16 [1.13, 1.20]) was higher for people with diabetes. Compared to the general population, a lower risk of hospitalisation was observed for lower extremity injury (0.96 [0.95, 0.98]), abdominal (0.65 [0.64, 0.66]), vertebral (0.88 [0.86, 0.90]), and upper extremity (0.91 [0.90, 0.92]) injury. Compared to the general population, higher risk of injury was observed in people with type 1 diabetes (1.40 [1.37, 1.44]) and type 2 diabetes using insulin (1.27 [1.26, 1.29]), but the risk was lower in those not using insulin (0.92 [0.91, 0.93]). Falls were the primary cause of injury in people with diabetes.
Conclusion: Diabetes, especially those using insulin exhibited higher risk of hospitalisation for injury. Diabetes interventions should consider falls prevention strategies including building muscle strength.

Disclosure
B.E. Feleke: None.
136-OR: Examining New-Onset Type 1 Diabetes Educational Practices among Centers in the T1D Exchange Quality Improvement Collaborative (T1DX-QI)
Authors: MCDONOUGH RYAN , OSPELT EMMA L. , EBEKOZIEN OSAGIE , SCHULMEISTER CAROLINE , RIOLES NICOLE , HARDISON HOLLY , PLANTE DEBORAH , MUCCI ANDREA , MATHIOUDAKIS NESTORAS N. , RAMAN VANDANA , CLEMENTS MARK A. , COLLABORATIVE T1DX-QI 
Published: June 2024

Background: The diagnosis of Type 1 Diabetes (T1D) requires immediate comprehensive education for people with T1D (PWD) and their caregivers. Educational content, delivery, methodology, location, and duration are not standardized. This study aims to evaluate the current state of new-onset diabetes education among T1DX-QI centers.
Methods: A survey was administered from July to September 2023 to 55 T1DX-QI centers. Descriptive analysis was completed.
Results: 50 of 55 centers (91%) completed the survey. Education consists of 5+ sessions (15%), 4 sessions (42%), 3 sessions (17%), 2 sessions (17%), and 1 session (2%). Communication immediately after diagnosis between PWD/family & care teams occurs daily (33%) or every 2-3 days (25%), and 21% is PWD/family initiated. Common communication modalities included phone calls (77%) and portal messages (19%). Education topics and session processes during new-onset visits were highly varied (Fig 1a). Pediatric centers frequently (85%) have patients consume a meal to aid in skill acquisition related to carb counting and dosing while no adult centers do. Criteria for considering outpatient teaching also varied by pediatric and adult centers. (Fig 1b)
Conclusions: Across T1DX-QI, practices related to new-onset education vary widely. Additional research is necessary to evaluate best-practices as they relate to T1D.

Disclosure
R. McDonough: Speaker's Bureau; Provention Bio, Inc. E.L. Ospelt: None. O. Ebekozien: Advisory Panel; Sanofi, Medtronic. Research Support; Vertex Pharmaceuticals Incorporated. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; Medtronic, Lilly Diabetes, Abbott, Dexcom, Inc. C. Schulmeister: None. N. Rioles: None. H. Hardison: None. D. Plante: None. A. Mucci: None. N.N. Mathioudakis: None. V. Raman: None. M.A. Clements: Research Support; Abbott. Consultant; Glooko, Inc. Research Support; Dexcom, Inc.

Funding
Helmsley Charitable Trust
1363-P: Diabetes Control and Complications in West India—Three-Year Results of LANDMARC Trial
Authors: JOSHI SHASHANK R. , SETHI BIPIN , GOPALAKRISHNAN UNNIKRISHNAN AMBIKA , CHAWLA MANOJ S. , PATANGE SONALI A. , SHAH TEJAS , JOSHI AMEYA S. , GOKALANI RUTUL , GANDHI PRAMOD D. , MENON SHALINI K. , GADEKAR ARVIND , CHODANKAR DEEPA 
Published: June 2024

Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 81 sites in West India (Ahmedabad, Mumbai, and Pune) included 1351 participants (mean [SD] baseline [BL] age: 53.2 [9.1] years, T2D duration: 8.9 [5.8] years and A1C: 7.9% [1.5]). At BL, most were insulin-naïve (n=1037; 77.4%), mainly on OADs (n=1013; 76.9%). At 3 years, 68.2% (n=733) were on OADs only, while 29.8% (n=320) were on insulin + OADs. Biguanides was the most prescribed class (BL: 1253 [93.5%] and 3-years: 1007 [93.7%]). Basal insulin usage increased from BL (n=203; 15.2%) to 3 years (n=237; 22.1%). Mean (SD) A1C, FPG, and PPG decreased by 0.4 (1.5) %, 7.2 (48.2) mg/dL, and 16.5 (73.8) mg/dL, respectively; and an increase in proportion of participants with A1C&lt;7% (BL: 257/920 [27.9%]; 3 years: 250/940 [34.4%]), was noted. Myocardial infarction and neuropathy were the most common macro and microvascular complications, respectively (Table). Hypertension and dyslipidemia were most common CV risk factors. West India had the highest proportion of participants with CV risk factors. An understanding of pivotal regional trends in glycemia, therapy, and complications may help strategize future diabetes management practices in India.

Disclosure
S.R. Joshi: Consultant; Twin Health, Marico, Franco Indian, Zydus Cadila, Glenmark Pharmaceuticals. Other Relationship; Novo Nordisk, Sanofi, MSD, Abbott Nutrition, Abbott, Biocon, Alkem, USV Private Limited, Boehringer-Ingelheim. B. Sethi: Other Relationship; Aventis, Novo Nordisk, Eli Lilly and Company, Boehringer-Ingelheim, Merck Sharp & Dohme Corp. A. Unnikrishnan: Speaker's Bureau; Sanofi. Other Relationship; Novo Nordisk. Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Abbott, Intas Pharmaceuticals Ltd. Research Support; Torrent Pharmaceuticals Ltd. M.S. Chawla: Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Biocon. Speaker's Bureau; Biocon. Advisory Panel; Eris Lifesciences Ltd. Speaker's Bureau; Eris Lifesciences Ltd. Advisory Panel; Torrent Pharmaceuticals Ltd. Speaker's Bureau; Torrent Pharmaceuticals Ltd. Advisory Panel; USV Private Limited, Lupin Pharmaceuticals, Inc. S.A. Patange: None. T. Shah: None. A.S. Joshi: None. R. Gokalani: None. P.D. Gandhi: None. S.K. Menon: Employee; Sanofi. A. Gadekar: None. D. Chodankar: Employee; Sanofi.

Funding
Sanofi
137-OR: Outcomes of Real-World Deployment of the Dulce Digital Texting Education Platform for Low-Income Diverse Populations with Diabetes
Authors: RUIZ MONICA , PHILIS-TSIMIKAS ATHENA , ORENDAIN NATALIA , TAVAKE-PASI OTOLOSE F. , STAVINOHA KERRY , ROMO NOEMI G. , EVANCHA NICOLE , LEVEN ERIC 
Published: June 2024

Introduction: Minorities are disproportionally impacted by T2D and have higher disease morbidity; however, prognosis improves with good glucose control. Dulce Digital (DD), a simple low-cost text message program with educational, motivational and glucose reminder messages delivered 2-3 times/day over 6 months has lowered HbA1c in RCTs for diverse low SES populations.
Objective: Evaluate the reach and effectiveness of DD in real-world community settings.
Methods: DD was offered throughout Southwest US sites serving low income, mostly Hispanic and Pacific Islander communities with T2D. Tailored feedback was provided based on blood glucose (BG) responses. Responses to BG prompts were categorized as follows: below 70; 71-130; 131-180; 181-250; and over 250; and analyzed using chi-square.
Results: From Jan 2021 to Dec 2023, N=1724 participants were enrolled from 10 sites-Fig 1A. BG metrics demonstrate significant incremental improvements in time in target range (p &lt; .00001)-Fig 1B. There was enthusiastic adoption of DD by community sites with simple enrollment processes and minimal staff effort for deployment.
Conclusion: DD texting program improved BG metrics, with greater time in range for low-income diverse communities. Outreach to enroll patients in community clinic settings and outreach events can be successful and serve as an enhanced approach to support DSME/S.

Disclosure
M. Ruiz: None. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc., Lilly Diabetes, Novo Nordisk, Sanofi, Medtronic, Bayer Inc. N. Orendain: None. O.F. Tavake-Pasi: None. K. Stavinoha: None. N.G. Romo: None. N. Evancha: None. E. Leven: None.

Funding
National Institutes of Health (1OT2 HL156812NCATS; UM1TR004407)
1383-P: In the 21st Century, African Immigrants to the United States Do Not Value Obesity—The Africans in America Study
Authors: HURSTON JAMAIICA , WORTHY CHARLITA , HUEFNER ELIZA A. , SAYED MARIAM , DUBOSE CHRISTOPHER , MABUNDO LILIAN , HORLYCK-ROMANOVSKY MARGRETHE F. , SUMNER ANNE E. 
Published: June 2024

With acculturation superimposed on nutritional transitions, urbanization and globalization, 21st century attitudes of African immigrants towards optimal body size are unknown. To gain perspective on body image, we assessed in 412 Africans living in America: 1) ideal body size 2) body size dissatisfaction and 3) cardiometabolic health by body size category. Participants chose 2 silhouettes from the Stunkard Figure Rating Scale, one for their wish body size and one for their perceived body size. The scale has 9 silhouettes corresponding to body size categories: Underweight: 1-2; Normal-Weight: 3-4; Overweight: 5-7; Obesity: 8-9. Body size dissatisfaction was calculated as the difference between perceived and wish body size. Cardiometabolic health was determined by BP, glucose and lipids. Enrollees lived in the Washington, DC area (BMI 27.9±4.6 (mean±SD), range 19.5-47.3 kg/m2, female: 42% (174/412); age 39±11y, range 20-69y). As their wish body size, no one (0/412) chose silhouettes in the obese category. In fact, the body size silhouettes most preferred were in the normal-weight category. Dissatisfaction because perceived body size was too large occurred in 63% (260/412). Whereas dissatisfaction because body size was too small occurred in 12% (49/412). However, body size dissatisfaction was higher in women than men (84% (146/174) vs. 69% (164/238), P&lt;0.001). BMI of women who thought they were too large was 30.3±4.6 kg/m2. Their wish body size silhouettes were: 1 to 6. BMI of women who thought they were too small was 23.4±3.3 kg/m2. Their wish body size silhouettes were: 3 to 6. BMI of men who thought they were too large was 29.2±3.9 kg/m2 and they chose for their wish body size: 1 to 5. BMI of men who thought they were too small was 23.0±2.7 kg/m2. Their wish silhouettes were: 4 to 6. Cardiometabolic health was most optimal for women and men with normal-weight BMI. Overall, Africans living in America did not value obesity and preferred a healthier normal-weight body size.

Disclosure
J. Hurston: None. C. Worthy: None. E.A. Huefner: None. M. Sayed: None. C. DuBose: None. L. Mabundo: None. M.F. Horlyck-Romanovsky: None. A.E. Sumner: None.
1386-P: Cause-Specific Mortality Is Diversifying in Those with Diabetes—A Multicountry Analysis
Authors: MAGLIANO DIANNA J. , MORTON JEDIDIAH I. , CHEN LEI , SACRE JULIAN W. , CARSTENSEN BENDIX , GREGG EDWARD W. , PAVKOV MEDA E. , ARFFMAN MARTTI , LUAN CHU MANH , EEG-OLOFSSON KATARINA , FLEETWOOD KELLY , FOSSE-EDORH SANDRINE , GUION MARIE , GUREVICIUS ROMUALDAS , HWA HA KYOUNG , KAUL PADMA , JUNG KIM DAE , LAURBERG TINNE , WILD SARAH , SHAW JONATHAN E. 
Published: June 2024

Objective: This multi-country study explored trends in causes of death in people with diabetes.
Methods: We used cause-specific mortality data in people with diabetes from 9 high-income countries (2000-2020). Data were from registries, health insurance, or other administrative sources. Proportional contributions of causes of death to total deaths across 10 groups (cancer, cardiovascular [CVD], dementia, diabetes, influenza and pneumonia, infection, liver, renal, respiratory disease, and all others) were age-standardized and regressed against time.
Results: We included 1,624,100 deaths from 9 jurisdictions. In all jurisdictions, there was a shift in the most common causes of death away from CVD and diabetes. The decline in the proportion of deaths due to CVD ranged from 0.34% to 2.32% per year (all Ptrend &lt; 0.001). Deaths due to diabetes declined in 8/9 jurisdictions with magnitudes from 0.09% to 0.87% per year but rose in Lithuania (0.64% per year). Dementia deaths rose in 8/9 jurisdictions (0.07% to 0.52% per year) as did the proportion of deaths due to ‘other’ causes. Cancer deaths rose in 5/9 jurisdictions. Trends in the remaining cause-of-death categories showed varied patterns.
Conclusion: There has been a shift in causes of death among those with diabetes away from CVD and diabetes. The increasing proportion of deaths due to dementia and cancer may require consideration when planning resource allocation.

Disclosure
D.J. Magliano: None. J.I. Morton: None. L. Chen: None. J.W. Sacre: None. B. Carstensen: Stock/Shareholder; Novo Nordisk. E.W. Gregg: None. M.E. Pavkov: None. M. Arffman: Research Support; Roche Pharmaceuticals. M. Chu: None. K. Eeg-Olofsson: Other Relationship; Abbott, Eli Lilly and Company, Novo Nordisk, Sanofi. K. Fleetwood: None. S. Fosse-Edorh: None. M. Guion: None. R. Gurevicius: None. K. Ha: None. P. Kaul: None. D. Kim: None. T. Laurberg: None. S. Wild: Other Relationship; Novo Nordisk, Novo Nordisk Foundation. J.E. Shaw: Advisory Panel; GlaxoSmithKline plc. Research Support; AstraZeneca. Advisory Panel; AstraZeneca. Speaker's Bureau; AstraZeneca, Roche Diabetes Care, Boehringer-Ingelheim, Zuellig Pharma Holdings Pte. Ltd. Advisory Panel; Novo Nordisk. Speaker's Bureau; Roche Diagnostics. Advisory Panel; Roche Diagnostics, Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Abbott, Mylan. Speaker's Bureau; Sanofi.

Funding
Centers for Disease Control and Prevention, United States
1397-P: Description of Prescribing Patterns of Antihyperglycemic Medications among Racially and Ethnically Diverse Populations in the All of Us Dataset
Authors: BRADY VERONICA J. , AKYIREM SAMUEL , PADHYE NIKHIL 
Published: June 2024

Introduction & Objectives: Minorities living with diabetes are more likely to have poorer glycemic outcomes compared to their White counterparts. Equitable access to novel anti-hyperglycemic medications can help improve health outcomes. The purpose of this study is to determine racial and ethnic disparities in prescribing patterns of anti-diabetic medications among persons with type 2 diabetes (T2D).
Methods: Participants were drawn from the All of Us research (AoU) program. Cases of T2D were identified using pre-defined, validated phenotype algorithm. Additionally, we identified individuals with T2D who had ever had a prescription of metformin, sulfonylureas, insulin, GLP1-RA, and SGLT2i. Multivariable logistic regression was used to assess if prescription patterns differ by race and ethnicity while adjusting for sociodemographic and clinical variables.
Results: Our analytic sample included 10,016 persons with T2D. Most participants were women (56.6%), White (51.7%), and had average HbA1C of &lt; 7% (57.2%). Blacks (aOR = 0.72, 95% CI: 0.66 - 0.79) and Hispanics (aOR = 0.81, 95% CI: 0.73 - 0.90) compared to White participants were less likely to receive GLP1-RA prescription. Additionally, Blacks were less likely to receive SGLT2i (aOR = 0.86, 95% CI: 0.78-0.96) but more likely to receive metformin (aOR = 1.33, 95% CI: 1.21-1.45). Blacks (aOR = 0.81, 95% CI: 0.74 - 0.88) and Hispanics (aOR = 0.75, 95% CI: 0.68 - 0.83) were less likely to receive insulin therapy.
Conclusions: Our findings, highlight racial and ethnic disparities in prescribing patterns. These findings provide evidence that these differences are independent of socioeconomic status and may be a factor in worse health outcomes experienced by racial minorities with T2D.

Disclosure
V.J. Brady: Board Member; Association of Diabetes Care & Education Specialists. Other Relationship; Diathrive. S. Akyirem: None. N. Padhye: None.

Funding
American Association of Colleges of Nursing (AACN)
1409-P: Changing Trends in Glucose-Lowering Drug Initiation for Type 2 Diabetes in the Era of Tirzepatide
Authors: PATORNO ELISABETTA , TESFAYE HELEN , ORTEGA-MONTIEL JANINNE , ALIX CAROLINE , DICESARE ELYSE C. , JANE CROMER SARA , WEXLER DEBORAH J. , PAIK JULIE M. 
Published: June 2024

Introduction & Objective: Clinical trials in adults with type 2 diabetes (T2D) have shown remarkable reductions in A1c and body weight for tirzepatide, the first dual GIP/GLP-1 receptor agonist approved in the US for T2D. The utilization trends and uptake of tirzepatide in adults with T2D in the US remain unexplored.
Methods: Using a US commercial claims database, we identified adults ≥18 years with T2D who initiated glucose-lowering drugs between 1/2021 and 6/2023 and plotted monthly drug initiation trends before and after the approval of tirzepatide for T2D (5/2022). We also compared the uptake of tirzepatide to the historical uptake of other GLP-1 receptor agonists (GLP-1RA) during the first 13 months since their initial approval for T2D.
Results: Between 1/2021 and 6/2023, metformin use decreased (from 25.5% to 20.7% of all glucose-lowering drug initiators), whereas GLP-1RA and SGLT2i use increased (from 17.6% to 23.0% and from 15.6% to 20.0%) (Fig. Panel A). The use of tirzepatide increased steeply after 10/2022, reaching 11.5% in 6/2023. By 6/2023, GLP-1RA were the most frequently initiated glucose-lowering drugs. During the first 13 months after approval, tirzepatide uptake was much steeper than any other GLP-1RA (Fig. Panel B).
Conclusion: Tirzepatide and other GLP-1RA are now the most frequently initiated glucose-lowering drugs for T2D. The uptake of tirzepatide is unprecedented with respect to any other GLP-1RA.

Disclosure
E. Patorno: Research Support; Boehringer-Ingelheim, Food and Drug Administration (FDA), National Institutes of Health, Patient-Centered Outcomes Research Institute. H. Tesfaye: None. J. Ortega-Montiel: None. C. Alix: None. E.C. DiCesare: None. S. Cromer: Other Relationship; Johnson & Johnson Medical Devices Companies. Advisory Panel; Alexion Pharmaceuticals, Inc. Other Relationship; Wolters Kluwer Health. D.J. Wexler: Other Relationship; Novo Nordisk. J.M. Paik: None.

Funding
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School
1446-P: Gender Inequalities in Cardiovascular Risk Factors in Primary Prevention Adults Living with Type 1 Diabetes in Germany and France—Findings from DPV and SFDT1
Authors: COSSON EMMANUEL , AUZANNEAU MARIE , AGUAYO GLORIA A. , KARGES WOLFGANG , RIVELINE JEAN-PIERRE , AUGSTEIN PETRA , SABLONE LAURA , JEHLE PETER M. , FAGHERAZZI GUY , HOLL REINHARD W. ,   STUDY GROUP SFDT1
Published: June 2024

Introduction & Objectives: To evaluate whether medical care for and level of cardiovascular risk factors differ in primary prevention between adult men and women with type 1 diabetes (T1D) in two European countries in 2020-2022.
Methods: We included 2657 participants from the DPV registry (Germany, mean age 40±15, diabetes duration 23±14 years; 50.9% men) and 1172 from the SFDT1 study (France, age 39±14, diabetes duration 22±13 years; 53.2% men).
Results: HbA1c levels and body mass indexes were similar in women and men with similar proportions of HbA1c&lt;7% (DPV: 36.6 vs. 33.0%, respectively; SFDT1: 22.8 vs. 24.9%; both n.s.). Women had less overweight in DPV (55.4 vs. 61.0%, p&lt;0.05) but not in SFDT1 (48.0 vs. 44.9%, n.s.) and were less prone to smoke (DPV: 19.7 vs. 25.8%, p&lt;0.05; SFDT1: 21.0 vs. 26.0%, n.s.). Systolic blood pressure was lower in women than men (DPV: 124±15 vs. 129±15; SFDT1: 121±16 vs. 126±14mmHg, both p&lt;0.05) with similar rates of antihypertensive therapy in case of systolic/diastolic blood pressure ≥140/90mmHg (DPV: 70.5 vs. 63.6%; SFDT1: 73.3 vs. 68.6%, both n.s.). In case of microalbuminuria, ACEi-ARB were less prescribed in women than men in DPV (21.4 vs 37.6%, p&lt;0.05) but not SFDT1 (70.6 vs 62.0%, n.s.). In women compared to men, HDL-cholesterol levels were higher; triglycerides lower and LDL-cholesterol similar in DPV and SFDT1. In those with LDL-cholesterol &gt;130 mg/dL (DPV: 19.9 vs. 23.9%; SFDT1 17.0 vs. 19.2%, both n.s.), statin therapy was less prescribed in women than men in DPV (7.9 vs. 17.0%, p&lt;0.05), SFDT1 (18.2 vs. 21.0%, n.s.).
Conclusion: Women in primary prevention have a better cardiovascular risk profile than men in both studies. We observed a high rate of therapeutic inertia, which might be higher in women for statin and nephroprotection with ACEi-ARB especially in Germany.

Disclosure
E. Cosson: Advisory Panel; Abbott, AstraZeneca, Lilly Diabetes, Novo Nordisk, Sanofi, Roche Diagnostics, Novartis AG, Amgen Inc. M. Auzanneau: Other Relationship; Insulet Corporation. G.A. Aguayo: None. W. Karges: None. J. Riveline: Board Member; Abbott, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Inc., Insulet Corporation, Air Liquide, AstraZeneca. P. Augstein: None. L. Sablone: None. P.M. Jehle: None. G. Fagherazzi: Speaker's Bureau; Sanofi. Advisory Panel; Timkl, SAB Biotherapeutics, Inc., Vitalaire, Roche Diabetes Care. R.W. Holl: None.
1451-P: Burden of Type 1 Diabetes Mellitus (T1DM) and Its Trend in G20 Countries from 1990–2019—A Benchmarking Analysis
Authors: ISLAM HAMZA , POTLURI GEETHIKA , MARKANDU KEETHANSHAN , PARISAPOGU ANUSHA , TEJA CHINTHAPALLI MRUNAL , MADDINENI KAVYA , ISLAM RABIA , DEKHNE ANUSHKA , DINESHBHAI DESAI HARDIK 
Published: June 2024

Introduction: Globally, Type 1 Diabetes (T1DM) has been increasing and affected 15.8 million people of all ages in G20 countries in 2019. This study aims to outline the T1DM burden in G20 countries, which hold substantial global population and economic influence.
Method: Using the Global Burden of Disease method, non-fatal health outcomes were estimated with DISMOD-MR 2.1, and fatal outcomes were evaluated using CODEm, stratified by age, gender, year, and location in G20 countries from 1990-2019.
Results: From 1990-2019, there was a substantial increase in T1DM prevalence, with a 99% rise in cases, a 31% increase in deaths, and a 40% increase in disability-adjusted life years (DALYs) within G20 countries. France and Saudi Arabia had the highest increases in age-standardized incidence rates (ASIR) at 138% and 112%, respectively. In terms of death rates, India had a 1% increase, while other countries showed decreases. Males had a higher burden than females, with higher incidence (27% vs. 22%), deaths (14% vs. -12%), and DALYs (17% vs. -0.03%) from 1990-2019. The highest incidence was among 5-9-year-olds, and the highest number of deaths occurred in those aged 95 and above in 2019.
Conclusion: T1DM contributed to 55.4% of all T1DM-related deaths worldwide within the G20 countries. Gender disparities are evident, with higher burdens observed in males, and age-specific care is crucial.

Disclosure
H. Islam: None. G. Potluri: None. K. Markandu: None. A. Parisapogu: None. M. Chinthapalli: None. K. Maddineni: None. R. Islam: None. A. Dekhne: None. H. Desai: None.